Dada Reyad, El Sayed Mohamed, Zekri Jamal
, , and , King Faisal Specialist Hospital and Research Center, Jeddah; and , Al-Faisal University, Riyadh, Kingdom of Saudi Arabia; and , Cairo University, Cairo, Egypt.
J Glob Oncol. 2016 Nov 16;3(5):455-458. doi: 10.1200/JGO.2016.006924. eCollection 2017 Oct.
Capecitabine, an oral fluorouracil (5-FU) derivative, has replaced 5-FU in many chemotherapy regimens used in various GI tract cancers. The experience with capecitabine in nasopharyngeal carcinoma (NPC) is limited.
We report on eight patients with locally advanced NPC treated with neoadjuvant chemotherapy with capecitabine and cisplatin.
All eight patients responded well to the chemotherapy combination and achieved complete remission after definitive chemoradiotherapy. No grade 3/4 toxicities were observed. Five patients experienced a relapse after 6, 8, 9, 12, and 17 months.
In the patients studied, capecitabine (in combination with cisplatin) was a safe and effective substitution for 5-FU for the neoadjuvant treatment of locally advanced NPC. Larger prospective clinical studies are required to confirm these results.
卡培他滨是一种口服氟尿嘧啶（5-FU）衍生物，在多种胃肠道癌症的化疗方案中已取代5-FU。卡培他滨在鼻咽癌（NPC）中的应用经验有限。
我们报告了8例局部晚期鼻咽癌患者，接受了卡培他滨和顺铂的新辅助化疗。
所有8例患者对化疗联合方案反应良好，在确定性放化疗后实现完全缓解。未观察到3/4级毒性反应。5例患者在6、8、9、12和17个月后复发。
在所研究的患者中，卡培他滨（联合顺铂）是5-FU用于局部晚期鼻咽癌新辅助治疗的安全有效替代药物。需要更大规模的前瞻性临床研究来证实这些结果。
